晚期前列腺癌的前列腺特异性膜抗原PET标准化成像
本文讨论晚期前列腺癌PSMA-PET/CT的标准化报告与疗效评估框架,包括PROMISE与PSMA-RADS报告体系,以及基于PSMA-PET肿瘤体积的预后与疗效生物标志物价值,并介绍PPP与RECIP疗效评估标准及其局限性。
要点
- PSMA-PET/CT已成为晚期前列腺癌的参考标准检查。
- PROMISE框架推荐按器官系统量化肿瘤体积,以反映转移部位对生物学侵袭性的影响。
- PSMA表达下降可能被误判为治疗有效,是PSMA体系的一个陷阱。
核心结论
- PSMA-PET/CT已成为晚期前列腺癌的参考标准检查,标准化报告与疗效评估框架对疾病范围纵向刻画、治疗选择与疗效评价具有重要价值。
- PSMA-PET衍生的肿瘤体积是预后判断的有用生物标志物,其变化是有前景的疗效评估生物标志物。
- 肿瘤体积并非总适合用于疗效评估,PSMA表达下降可能被错误解读为治疗有效。
研究设计与样本
- 本文为综述,讨论晚期前列腺癌PSMA-PET/CT的标准化报告与疗效评估框架及相关证据。
主要发现
- PROMISE框架推荐按器官系统量化肿瘤体积,考虑转移部位对生物学侵袭性的影响。
- PSMA-PET衍生肿瘤体积的变化已被证明是有前景的疗效评估生物标志物。
- PSMA表达下降可能被错误解读为治疗有效,是PSMA体系的一个陷阱。
- 对于病变有限的患者,肿瘤体积可能不是疗效评估的理想指标。
- PPP标准与RECIP标准分别针对晚期前列腺癌较早和较晚表型进行优化。
关键数值与推荐
- PROMISE框架推荐按器官系统量化肿瘤体积。
- 确定PPP或RECIP结果的变量记录在PROMISE推荐框架下。
- PSMA-RADS为PSMA靶向PET成像的结构化报告系统。
临床怎么用
- 原文未据此给出推荐。
局限性
- 肿瘤体积可能并非总适合用于疗效评估。
- PSMA表达下降可能被错误解读为治疗有效,是PSMA体系的一个陷阱。
- 对于病变有限的患者,肿瘤体积可能不是疗效评估的理想指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imaging of advanced prostate cancer is a challenging task, as it requires longitudinal characterization of disease extent in a standardized way to enable appropriate treatment selection and evaluation of treatment efficacy. In the last years, prostate-specific membrane antigen (PSMA)-PET/CT has become the reference standard examination for patients with advanced prostate cancer. Together with the rise of PSMA-PET, standardized frameworks for the reporting of image findings have been proposed, eg, the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) and the structured reporting system for PSMA targeted PET imaging (PSMA-RADS) framework. Therefore, recent evidence on PSMA-PET derived tumor volume as useful a biomarker for outcome prognostication and related frameworks will be discussed in the article. The PROMISE framework recommends quantifying the tumor volume per-organ system, which accounts for the fact that the location of the metastases greatly influence its biological aggressiveness. In addition, changes in PSMA-PET derived tumor volume have been shown to be promising biomarkers for response assessment. Limitations of PSMA-PET will also be discussed because the tumor volume might not always be suited for response assessment. As a pitfall of PSMA-based systems, decreasing PSMA-expression might erroneously be interpreted as response to therapy. Also, especially for patients with limited disease, the tumor volume might not be ideal for response assessment. Therefore, various frameworks have been introduced to objectively measure response to therapy with PSMA-PET. Amongst these, the PSMA-PET progression (PPP) criteria and the response evaluation criteria in PSMA (RECIP) are optimized for earlier and later phenotypes of advanced prostate cancer, respectively. Variables needed to determine PPP or RECIP outcome on PSMA-PET are recorded under the umbrella of PROMISE recommendations. In this article, various reporting and response assessment frameworks are explained and discussed. Also, recent evidence for the relevance of PSMA-PET biomarkers for clinical management and outcome prognostication are shown.
引用
- Seifert R, Gafita A, Telli T, et al. Standardized PSMA-PET Imaging of Advanced Prostate Cancer. Semin Nucl Med. 2023. PMID: 37573199. doi:10.1053/j.semnuclmed.2023.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。